# Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor

> **NCT04149262** · — · COMPLETED · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 44 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Fast-acting insulin aspart
- **DRUG:** Rapid-acting insulin analogues (insulin aspart or insulin lispro)

## Key facts

- **NCT ID:** NCT04149262
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2020-03-31
- **Final completion:** 2023-02-15
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149262, "Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04149262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*